These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 7972939)
1. Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats. Otsuki M; Nakano S; Tachibana I Regul Pept; 1994 Jul; 52(2):85-95. PubMed ID: 7972939 [TBL] [Abstract][Full Text] [Related]
2. CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats. Nakano S; Kihara Y; Otsuki M Pancreas; 1998 Mar; 16(2):169-75. PubMed ID: 9510141 [TBL] [Abstract][Full Text] [Related]
3. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis. Nakano S; Tachibana I; Otsuki M Pancreas; 1995 Apr; 10(3):287-94. PubMed ID: 7542770 [TBL] [Abstract][Full Text] [Related]
4. Effect of chronic oral administration of the CCK receptor antagonist loxiglumide on exocrine and endocrine pancreas in normal rats. Imoto I; Yamamoto M; Jia DM; Otsuki M Int J Pancreatol; 1997 Dec; 22(3):177-85. PubMed ID: 9444548 [TBL] [Abstract][Full Text] [Related]
5. Effect of cholecystokinin1 receptor antagonist loxiglumide (CR1505) on basal pancreatic exocrine secretion in conscious rats. Ishizaki K; Kinbara S; Kawamura M; Kimura K; Shiratori K; Takeuchi T Pancreas; 2003 Jan; 26(1):87-91. PubMed ID: 12499923 [TBL] [Abstract][Full Text] [Related]
6. Effects of cholecystokinin receptor antagonist loxiglumide on rat exocrine pancreas. Nakano S; Tachibana I; Otsuki M Pancreas; 1994 Jul; 9(4):425-33. PubMed ID: 7937691 [TBL] [Abstract][Full Text] [Related]
7. Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate. Kimura K; Tominaga K; Fujii M; Saito T; Kasai H Arzneimittelforschung; 1998 Jan; 48(1):65-9. PubMed ID: 9522035 [TBL] [Abstract][Full Text] [Related]
8. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist. Baum F; Nauck MA; Ebert R; Cantor P; Hoffmann G; Choudhury AR; Schmidt WE; Creutzfeldt W Digestion; 1992; 53(3-4):189-99. PubMed ID: 1291406 [TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin receptor antagonist loxiglumide modulates plasma levels of gastro-entero-pancreatic hormones in man. Feedback control of cholecystokinin and gastrin secretion. Schmidt WE; Creutzfeldt W; Höcker M; Nustede R; Choudhury AR; Schleser A; Rovati LC; Fölsch UR Eur J Clin Invest; 1991 Oct; 21(5):501-11. PubMed ID: 1752290 [TBL] [Abstract][Full Text] [Related]
10. Defect in pancreatic exocrine and endocrine response to CCK in genetically diabetic OLETF rats. Tachibana I; Akiyama T; Kanagawa K; Shiohara H; Furumi K; Watanabe N; Otsuki M Am J Physiol; 1996 Apr; 270(4 Pt 1):G730-7. PubMed ID: 8928805 [TBL] [Abstract][Full Text] [Related]
11. Pancreatic fluid hypersecretion in rats after acute pancreatitis. Czakó L; Yamamoto M; Otsuki M Dig Dis Sci; 1997 Feb; 42(2):265-72. PubMed ID: 9052504 [TBL] [Abstract][Full Text] [Related]
12. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans. Hildebrand P; Ensinck JW; Ketterer S; Delco F; Mossi S; Bangerter U; Beglinger C J Clin Endocrinol Metab; 1991 May; 72(5):1123-9. PubMed ID: 2022712 [TBL] [Abstract][Full Text] [Related]
13. Comparison of loxiglumide, a cholecystokinin receptor antagonist, and atropine on hormonal and meal-stimulated pancreatic secretion in man. Gabryelewicz A; Kulesza E; Konturek SJ Scand J Gastroenterol; 1990 Jul; 25(7):731-8. PubMed ID: 2396088 [TBL] [Abstract][Full Text] [Related]
14. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas. Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo. Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600 [TBL] [Abstract][Full Text] [Related]
16. Duration and potency of anticholecystokinin action of subcutaneous and oral loxiglumide on cerulein-stimulated pancreatic exocrine secretion. Watanabe N; Otsuki M Int J Pancreatol; 1993 Apr; 13(2):129-37. PubMed ID: 8501354 [TBL] [Abstract][Full Text] [Related]
17. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs. Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032 [TBL] [Abstract][Full Text] [Related]
18. Effects of the cholecystokinin A receptor antagonist loxiglumide on the proliferation and cell cycle time of pancreatic acinar cells in rats. Kanemitsu D; Sakagami J; Motoyoshi T; Nakajima T; Kataoka K Pancreas; 2006 Mar; 32(2):190-6. PubMed ID: 16552340 [TBL] [Abstract][Full Text] [Related]
19. Effects of proglumide on cholecystokinin-8-induced exocrine and endocrine pancreatic responses in conscious sheep. Mineo H; Iwaki N; Kogishi K; Onaga T; Kato S; Zabielski R Comp Biochem Physiol A Physiol; 1997 Nov; 118(3):759-64. PubMed ID: 9406447 [TBL] [Abstract][Full Text] [Related]
20. Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models. Tani S; Okabayashi Y; Nakamura T; Fujii M; Itoh H; Otsuki M Pancreas; 1990 May; 5(3):284-90. PubMed ID: 2343042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]